Fineline Cube

Follow:
14422 Articles
Eisai China Partners with DSM‑Firmenich’s i‑Health to Bring Lactéol to Mainland China
CompanyDeals

Eisai China Partners with DSM‑Firmenich’s i‑Health to Bring Lactéol to Mainland China

Biocytogen Eyes A‑Share Listing on Shanghai’s STAR Market to Fund Preclinical R&D Growth
CompanyDeals

Biocytogen Eyes A‑Share Listing on Shanghai’s STAR Market to Fund Preclinical R&D Growth

Jiangsu Hengrui HRS‑5635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis B
CompanyDrug

Jiangsu Hengrui HRS‑5635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis B

Roche Announces $2.4 B Acquisition of 89bio, Targeting Liver and Cardiometabolic Therapies
CompanyDeals

Roche Announces $2.4 B Acquisition of 89bio, Targeting Liver and Cardiometabolic Therapies

Eli Lilly’s Mounjaro Shows Promising Results in Children with Type 2 Diabetes
CompanyDrug

Eli Lilly’s Mounjaro Shows Promising Results in Children with Type 2 Diabetes

Siemens Healthineers and Stryker Forge Neurovascular Robotics Alliance
CompanyDeals

Siemens Healthineers and Stryker Forge Neurovascular Robotics Alliance

China CDE Seeks Public Feedback on 98th Batch of Reference Standards for Generic Drugs
DrugPolicy / Regulatory

China CDE Seeks Public Feedback on 98th Batch of Reference Standards for Generic Drugs

Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1 B in Cardio siRNA Deal
CompanyDeals

Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1 B in Cardio siRNA Deal

Cook Medical & Siemens Healthineers Partner to Launch First Radiation‑Free iMRI Suite
CompanyDeals

Cook Medical & Siemens Healthineers Partner to Launch First Radiation‑Free iMRI Suite

Eli Lilly Unveils $5 B Virginia Facility to Scale Bioconjugate & Antibody Production
Company

Eli Lilly Unveils $5 B Virginia Facility to Scale Bioconjugate & Antibody Production

AstraZeneca China Decentralises Medical Affairs, Signals Shift in Global Strategy
Company

AstraZeneca China Decentralises Medical Affairs, Signals Shift in Global Strategy

Ascletis Pharma Reports 28‑Day ASC30 Study Results at EASD
CompanyDrug

Ascletis Pharma Reports 28‑Day ASC30 Study Results at EASD